In conjunction with STING agonists to promote T cell help and germinal center formation, a universal influenza nanovaccine is developed to elevate humoral responses against a conserved influenza peptide antigen, enabling single‐shot protection against heterotypic influenza viruses. Here, STING1 is linked to influenza.